Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers

Inclusion Criteria: * Written informed consent obtained. * Participants must be able to speak, read and understand German. * Good general health ascertained by detailed medical history and physical examinations. * Males 18-45 years (inclusive). * Body mass index (BMI) 18-30 kg/m2 inclusive * Weight 55-95 kg (inclusive). * Participants with female partners of child-bearing potential must adhere to a proper form of contraception from first study treatment administration until 3 months after the end-of-study visit. Exclusion Criteria: * A predictable poor compliance or inability to understand and comply with protocol requirements, instructions and protocol-stated restrictions or communicate well with the investigator. * Vulnerable subjects. * Veins unsuitable for repeated venipuncture. * Evidence of clinically relevant cardiovascular, renal, hepatic, haematological, gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator. The participants should be healthy subjects. * Subjects with a medical history of relevant psychiatric disorders or evidence of significant neuropsychiatric disease * Any condition requiring regular concomitant medication including herbal products or likely to need any concomitant medication during the study. * Definite or suspected personal history of hypersensitivity to drugs or excipients. * Intake of any medication that could affect the outcome of the study, as judged by the investigator, within 2 weeks before first study treatment administration (2 months for enzyme inducing drugs like rifampicin or carbamazepin), or less than 5 times the half-life of the medication. * A history of alcoholism or excess alcohol intake (including regular consumption of more than 21 units of alcohol per week) . * Use of nicotine-containing products within 6 months of admission and inability to refrain from using nicotine-containing products during the study. * History of drug abuse or positive drug screen for amphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, methamphetamine or methadone. * Propensity to get headache when refraining from caffeine-containing beverages. * Blood donation or loss of clinically relevant amount of blood within 2 months before the screening visit. * Abnormal 12-lead ECG finding of clinical relevance at the screening visit * Heart rate (HR) \< 50 bpm or \> 90 bpm after 10 min in rest (supine) at the screening visit * At the screening visit: systolic BP \< 90 mmHg or \> 140 mmHg, diastolic BP \< 50 mmHg or \> 90 mmHg, orthostatic hypotension decrease of greater than or equal to 20 mmHg for systolic BP, decrease of greater than or equal to 10 mmHg for diastolic BP. * Abnormal 24-h Holter of clinical relevance at the screening visit, * Positive serology to human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies. * Any abnormal value of laboratory, vital signs, or physical examination, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk for the subject if he takes part in the study. * Participation in an investigational drug study within 2 months before entry into this study. * An employee, a direct or indirect relative of the employee of the contract research organisation or the sponsor. * Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the subject. * Subject with abnormal standard EEG judged as clinically relevant by the investigator at screening.